Medtech Talk

Chen Yu, MD, managing director of Vivo Capital, has built a career finding the right deals at the right time in the US and China. Hear what US companies can do to take advantage of potential Pan Pacific opportunities.

Data guru Jon Norris, managing director at Silicon Valley Bank, reviews his first-half numbers for ophthalmology and life sciences. Norris’ first-half numbers for Medtech start-ups show some surprising sources of strength for the sector.

ReVision Optics built it – a corneal inlay capable of correcting presbyopia. The FDA approved it sooner than expected. Now the company needs to build it into a successful private-pay business.

Meet the newest Master of the Industry. Jim Mazzo, who has led divisions, spin-outs, and start-ups, now leads what looks to be a new leader in ophthalmology. Hear how Mazzo views this new opportunity for Zeiss and himself.

Over two decades ago, Mark Humayun – who will co-chair our upcoming OIS@ASRS meeting in San Francisco – helped launch a “moonshot” that would eventually restore vision for retinitis pigmentosa patients. In this podcast we discuss what drives him and what’s next for ophthalmology.

Cartiva secured an historic win when the FDA approved its synthetic cartilage. CEO Tim Patrick explains what it took to get the approval and how the company will sell going forward.

Eric Timko, the former CEO of Blue Belt, shares how the company used MAKO’s wake to build a market for its surgical robot and sell the business to Smith & Nephew. Timko explains the company’s fast-follower strategy and shares what he’s looking to do next.

The board at Ulthera, an aesthetics device company, faced an attractive dilemma. Take the company public? Or accept a lucrative buyout? Hear from the CEO how the company’s culture and approach led to that favorable outcome.

Gilde Healthcare Partner Geoff Pardo shares how the firm will invest its new $250 million in health care companies, including Medtech.